{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:57:36Z","timestamp":1781643456056,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      IgG subclass genes from chromosome 14q32.3 are assessed serologically by GM allotypes, genetic markers of the Fc part of the immunoglobulin constant heavy G chains, (\n                      <jats:italic>IGHG<\/jats:italic>\n                      (Fc\u03b3)(GM) genes. Alternative GM allotypes of IgG3, IgG1 and IgG2, respectively, define 6 unique, precise GM-specific IgG subclass genes, inherited the Mendelian way with allelic exclusion, and linkage disequilibrium of IgG3-IgG1. Increased number of homozygous GM-specific IgG subclass genotypes with total loss of alternative IgG subclass molecules, inborn errors of immunity (IEI), are found in severe immunological diseases.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A novel ELISA using GM-specific myeloma proteins and GM-specific monoclonals, identifies 6 alternative GM-specific IgG subclass genes and molecules IgG3*b &amp; IgG3*g, IgG1*f &amp; IgG1*a and IgG2*n &amp; IgG2*-n, with different structures and functions. 4 different IgG3-IgG1-IgG2 haplotypes encode 10 individual\n                      <jats:italic>IGHG<\/jats:italic>\n                      diplotypes from 10 innate lymphoid combined B cells in 587 healthy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The alternative GM-specific IgG subclass genes have different structures and functions and respond differently in immunotherapy to antigen stimulation with virus, bacteria and allergens. In this report we focus on excluded GM-IgG subclass genes, inborn errors of immunity (IEI) dominating in severe immunological diseases, severe infections, primary immunodeficiencies (PIDs), JCA, asthma, diabetes type 1 and malignancy. By intravenous immunoglobulins (IVIG) the excluded IgG subclass molecules are supplied and may prevent primary virus attacks and exacerbations in autoimmune disorders. IgG subclass genes orchestrate additional immune factors of inflammation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Excluded GM-specific IgG subclass genes, IEI explore diagnosis, pathogenesis, prognosis and different phenotypes in immunological diseases, with IVIG as treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10875-026-02001-5","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T04:03:46Z","timestamp":1774065826000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Excluded GM-specific IgG Subclass Genes in Health and Disease - Inborn Errors of Immunity"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2487-105X","authenticated-orcid":false,"given":"Vivi-Anne","family":"Oxelius","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"key":"2001_CR1","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1699-0463.1956.tb03392.x","volume":"39","author":"R Grubb","year":"1956","unstructured":"Grubb R. Agglutination of erythrocytes coated withincompleteanti-Rh by certain rheumatoid arthritic sera and some other sera. The excistence of human serum groups. Acta path Microbiol Scand. 1956;39:195\u20137.","journal-title":"Acta path Microbiol Scand"},{"key":"2001_CR2","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1126\/science.154.3752.1041","volume":"154","author":"HG Kunkel","year":"1966","unstructured":"Kunkel HG, Yount WJ, Litwin SD. Genetically determined antigen of the Ne subgroup of gammaglobulin: Detection by precipitin analysis. Science. 1966;154:1041\u201342.","journal-title":"Science"},{"key":"2001_CR3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/j.1365-3083.1993.tb01749.x","volume":"37","author":"V-A Oxelius","year":"1993","unstructured":"Oxelius V-A, Carlsson A-M. Quantitation of Gm allotypes. Scand J Immunol. 1993;37:143\u20138.","journal-title":"Scand J Immunol"},{"key":"2001_CR4","first-page":"31","volume":"6","author":"N Rautonen","year":"1989","unstructured":"Rautonen N, Seppala I, Hallberg T, Grubb R, M\u00e4k\u00e4l\u00e4 O. Determination of homozygosity or heterozygosity for the G2m(n) allotype by monoclonal precipitating antibodies. Exp Clin Immunogenet. 1989;6:31\u20138.","journal-title":"Exp Clin Immunogenet"},{"key":"2001_CR5","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1046\/j.1365-3083.1999.00521.x","volume":"49","author":"V-A Oxelius","year":"1999","unstructured":"Oxelius V-A. Preparation of IgG subclass allotypes from polyclonal IgG. Scand J Immunol. 1999;49:395\u20138.","journal-title":"Scand J Immunol"},{"key":"2001_CR6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1046\/j.1365-2249.1996.d01-851.x","volume":"106","author":"V-A Oxelius","year":"1996","unstructured":"Oxelius V-A, Eibl MM. Different Gm allotype levels in human intravenous Immunglobulin (IVIG) preparations, survival of foreign Gm allotypes in immunodeficient patients. Clin Exp Immunol. 1996;106:203\u20137.","journal-title":"Clin Exp Immunol"},{"key":"2001_CR7","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1046\/j.1365-3083.1999.00520.x","volume":"49","author":"V-A Oxelius","year":"1999","unstructured":"Oxelius V-A. Genetic B cell variation based on ImmunoGlobulin Heavy G chain (Gm) genes. Scand J Immunol. 1999;49:345\u20136.","journal-title":"Scand J Immunol"},{"key":"2001_CR8","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1046\/j.1365-3083.1999.00618.x","volume":"50","author":"V-A Oxelius","year":"1999","unstructured":"Oxelius V-A, Aurivillius M, Carlsson A-M, Musil K. Serum Gm allotype development during childhood. Scand J Immunol. 1999;50:440\u20136.","journal-title":"Scand J Immunol"},{"key":"2001_CR9","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.clim.2013.10.003","volume":"149","author":"V-A Oxelius","year":"2013","unstructured":"Oxelius V-A, Pandey JP. Human immunoglobulin constant heavy G chain (IGHG)(Fc\u03b3) (GM) genes, defining innate variants of IgG molecules and B cells, have impact on disease and therapy. Clin Immunol. 2013;149:475\u201386.","journal-title":"Clin Immunol"},{"key":"2001_CR10","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1111\/j.1651-2227.2005.tb01910.x","volume":"94","author":"M Aurivillius","year":"2005","unstructured":"Aurivillius M, Oymar K, Oxelius V-A. Immunoglobulin Heavy G2 chain (IGHG 2) gene restriction in the development of severe respiratory syncythial virus infection. Acta Paediatr. 2005;94:414\u20138.","journal-title":"Acta Paediatr"},{"key":"2001_CR11","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/S0140-6736(79)90584-1","volume":"I","author":"JP Pandey","year":"1979","unstructured":"Pandey JP, Fudenburg HH, Virella CU, Kyong CB, Loadholt RM, Galbraith EC, et al. Association between immunoglobulin allotypes and immune responses to Haemophilus influenzae and meningococcus polysaccharides. Lancet. 1979;I:190\u20132.","journal-title":"Lancet"},{"key":"2001_CR12","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000335592","volume":"159","author":"V-A Oxelius","year":"2012","unstructured":"Oxelius V-A. From genotypes of immunoglobulin constant heavy G chains, IGHG (Fc\u03b3) (GM) genes to phenotypes in childhood asthma. Int Arch Allergy Immunol. 2012;159:94\u2013102.","journal-title":"Int Arch Allergy Immunol"},{"key":"2001_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/j.1365-3083.1990.tb02765.x","volume":"31","author":"V-A Oxelius","year":"1990","unstructured":"Oxelius V-A. Lack of G2m(n) allotype in IgG subclass deficiency, in IgG2 deficiency together with lack of G1m(a) and G3m(g) and in IgG3 deficiency together with lack of G1m(f) and G3m(b). Scand J Immunol. 1990;31:243\u20137.","journal-title":"Scand J Immunol"},{"key":"2001_CR14","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.clim.2008.03.520","volume":"128","author":"V-A Oxelius","year":"2008","unstructured":"Oxelius V-A, Ochs H, Hammarstr\u00f6m L. Restricted immunoglobulin heavy G chain genes in primary immunodeficiencies. Clin Immunol. 2008;128:190\u20138.","journal-title":"Clin Immunol"},{"key":"2001_CR15","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000371351","volume":"166","author":"V-A Oxelius","year":"2015","unstructured":"Oxelius V-A, Krueger R, Ahlstedt S, Keil T, Lau S, Wahn U. Innate IgG molecules and innate B cells expressed by immuno- globulin constant heavy G chain (IGHG)(Fc\u03b3)(GM) genes are involved in the \u00b4allergic march\u00b4of IgE sensitization in children. Int Arch Allergy Immunol. 2015;166:25\u20139.","journal-title":"Int Arch Allergy Immunol"},{"issue":"1","key":"2001_CR16","doi-asserted-by":"publisher","first-page":"722","DOI":"10.4049\/jimmunol.177.1.722","volume":"177","author":"G J\u00f6nsson","year":"2006","unstructured":"J\u00f6nsson G, Oxelius V-A, Truedsson L, Braconier JH, Sturfelt G, Sj\u00f6holm AG. Homozygosity for the IgG2 subclass allotype G2M(n) protects against severe infections in hereditary C2 deficiency. J Immunol. 2006;177(1):722\u20138.","journal-title":"J Immunol"},{"key":"2001_CR17","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3109\/03009749309095140","volume":"22","author":"V-A Oxelius","year":"1993","unstructured":"Oxelius V-A, Svantesson H, Carlsson A-M. GM phenotype linkage to subsets of juvenile chronic arthritis (JCA). Scand J Rheum. 1993;22:284\u20138.","journal-title":"Scand J Rheum"},{"key":"2001_CR18","first-page":"47","volume":"67","author":"Y Nakao","year":"1981","unstructured":"Nakao Y, Matsumoto N, Miyazaki T, Watanabe S, Mukojima T, Kawashima R, Fujita T, Tsujt K. Immunoglobulin G heavy chain allotypes as possible genetic markers for human cancer. J Natl Cancer Inst. 1981;67:47\u201350.","journal-title":"J Natl Cancer Inst"},{"key":"2001_CR19","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1007\/s00262-009-0709-4","volume":"58","author":"JP Pandey","year":"2009","unstructured":"Pandey JP, Nietert PJ, Klaaman K, Kurtenkov O. A genetic variant of immunoglobulin gamma2 is strongly associated with immunity to mucin 1 in patients with breast cancer. Cancer Immunol Immunother. 2009;58:2025\u20139.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"2001_CR20","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1023\/B:JOCI.0000040927.15641.0c","volume":"24","author":"M Hahn-Zoric","year":"2004","unstructured":"Hahn-Zoric M, Ulanova M, Friman V, Bj\u00f6rkander J, Oxelius V-A, Lucas A, et al. Antibody response to the Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in healthy and infection-prone individuals with IgG3 subclass deficiency. J Clin Immunol. 2004;24(5):561\u201370.","journal-title":"J Clin Immunol"},{"key":"2001_CR21","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.cell.2006.07.024","volume":"126","author":"K Takahashi","year":"2006","unstructured":"Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663\u201376.","journal-title":"Cell"},{"key":"2001_CR22","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1002\/1521-4141(200009)30:9<2540::AID-IMMU2540>3.0.CO;2-S","volume":"30","author":"A Atherton","year":"2000","unstructured":"Atherton A, Armour KL, Bell S, Minson AC, Clark MR. The herpes simplex virus type 1 Fc receptor discriminate between IgG1 allotypes. Euro J Immunol. 2000;30:2540\u20137.","journal-title":"Euro J Immunol"},{"key":"2001_CR23","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1016\/j.molimm.2007.03.022","volume":"44","author":"AM Nambodiri","year":"2007","unstructured":"Nambodiri AM, Budkowska A, Nietert PJ, Pandey JP. Fc\u03b3 receptor-like hepatitis C virus core protein binds differentially to IgG of discordant Fc (GM) genotypes. Mol Immunol. 2007;44:3805\u20138.","journal-title":"Mol Immunol"},{"key":"2001_CR24","doi-asserted-by":"publisher","first-page":"332","DOI":"10.4161\/mabs.1.4.9122","volume":"1","author":"R Jefferis","year":"2009","unstructured":"Jefferis R, Lefranc MP. Human immunoglobulin allotypes: possible implications for immunogenicity. MAbs. 2009;1:332\u20138.","journal-title":"MAbs"},{"key":"2001_CR25","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1744-313X.1979.tb00684.x","volume":"6","author":"RR de Vries","year":"1979","unstructured":"de Vries RR, Meera Kahn P, Bernini LF, van Loghem E, van Rood JJ. Genetic control of survival in epidemics. J Immunogenet. 1979;6:271\u201387.","journal-title":"J Immunogenet"},{"issue":"7","key":"2001_CR26","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1651-2227.1995.tb13753.x","volume":"84","author":"B Schiller","year":"1995","unstructured":"Schiller B, Fasth A, Bj\u00f6rkhem G, Elinder G. Kawasaki disease in Sweden: Incidence and clinical features. Acta Paediatr. 1995;84(7):769\u201374.","journal-title":"Acta Paediatr"},{"key":"2001_CR27","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41577-020-0350-1","volume":"20","author":"A Moreira","year":"2020","unstructured":"Moreira A. Kawasaki disease linked to Covid-19 in children. Nat Rev Immunol. 2020;20:407.","journal-title":"Nat Rev Immunol"},{"key":"2001_CR28","doi-asserted-by":"crossref","unstructured":"Harada K, Ho H, Cunningham-Rundles C. Covid-19 prevalence and outcomes in patients receiving biologic therapies at an infusion center in New York City. Clin Immunol. 2021;230.","DOI":"10.1016\/j.clim.2021.108803"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-026-02001-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-026-02001-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-026-02001-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:35:44Z","timestamp":1781642144000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-026-02001-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2001"],"URL":"https:\/\/doi.org\/10.1007\/s10875-026-02001-5","relation":{},"ISSN":["1573-2592"],"issn-type":[{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,21]]},"assertion":[{"value":"1 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}